State Street’s Avita Medical RCEL Stock Holding History

State Street’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.59M	Buy	429,022 +10,691	+3%	+$44.9K	﹤0.01%	3365
2025 Q4	$1.44M	Sell	418,331 -4,977	-1%	-$19.9K	﹤0.01%	3433
2025 Q3	$2.16M	Sell	423,308 -105,476	-20%	-$550K	﹤0.01%	3315
2025 Q2	$2.8M	Buy	528,784 +1,832	+0.3%	+$13.3K	﹤0.01%	3191
2025 Q1	$4.29M	Sell	526,952 -8,019	-1%	-$74.9K	﹤0.01%	2941
2024 Q4	$6.85M	Buy	534,971 +14,974	+3%	+$177K	﹤0.01%	2827
2024 Q3	$5.57M	Buy	519,997 +11,997	+2%	+$113K	﹤0.01%	2911
2024 Q2	$4.02M	Sell	508,000 -433,041	-46%	-$4.12M	﹤0.01%	3024
2024 Q1	$15.1M	Buy	941,041 +440,733	+88%	+$7.13M	﹤0.01%	2335
2023 Q4	$6.86M	Buy	500,308 +31,167	+7%	+$357K	﹤0.01%	2785
2023 Q3	$6.85M	Buy	469,141 +16,912	+4%	+$286K	﹤0.01%	2772
2023 Q2	$7.69M	Buy	452,229 +364,384	+415%	+$5.35M	﹤0.01%	2783
2023 Q1	$1.23M	Buy	87,845 +4,200	+5%	+$44.7K	﹤0.01%	3468
2022 Q4	$552K	Sell	83,645 -500	-0.6%	-$3K	﹤0.01%	3740
2022 Q3	$443K	Hold	84,145	–	–	﹤0.01%	3824
2022 Q2	$400K	Sell	84,145 -334,982	-80%	-$2.07M	﹤0.01%	3922
2022 Q1	$3.55M	Sell	419,127 -363,878	-46%	-$3.35M	﹤0.01%	3335
2021 Q4	$9.38M	Buy	783,005 +50,130	+7%	+$764K	﹤0.01%	2951
2021 Q3	$13M	Sell	732,875 -80,254	-10%	-$1.51M	﹤0.01%	2730
2021 Q2	$16.7M	Buy	813,129 +368,380	+83%	+$7.26M	﹤0.01%	2611
2021 Q1	$8.81M	Buy	444,749 +151,597	+52%	+$3.53M	﹤0.01%	2794
2020 Q4	$5.45M	Buy	+293,152	New	+$6.43M	﹤0.01%	2919

Other funds holding RCEL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street's RCEL Position: Q1 2026 in Review

State Street increased its Avita Medical (RCEL) stake by 2.6% in Q1 2026, buying an estimated $44.9K and bringing the position to 429,022 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3365.

State Street first reported a position in RCEL in Q4 2020 and has held it in 22 quarters since. The position peaked at $16.7M in Q2 2021. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

State Street held 429,022 shares of Avita Medical worth $1.59M as of Q1 2026.
State Street bought 10,691 Avita Medical shares in Q1 2026, an estimated $44.9K.
Avita Medical made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3365 holding.
State Street first reported a position in Avita Medical in Q4 2020 and has held it in 22 quarters since.
State Street's Avita Medical position peaked at $16.7M in Q2 2021.
79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.